TrialMedical oncology (Northwood, London, England)2014

Phase II study of low-dose fixed-rate infusion of gemcitabine combined with cisplatin and dexamethasone in resistant non-Hodgkin lymphoma and correlation with Bcl-2 and MDR expression.

Shereef Elsamany et al.PubMed ↗Publisher ↗

No numbers read from the abstract.